Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

30-Day Mortality Rate After Admission for HF

Am J Med; ePub 2017 Sep 20; Faillace, et al

A majority of heart failure (HF) related mortality occurred in patients who opted for a do not resuscitate (DNR) status with end-stage HF, thus limiting the appropriateness of administering evidence-based therapies. This according to a recent study that evaluated the Centers for Medicare and Medicaid Services’ (CMS) 30-day risk-adjusted mortality model and concluded that it fails to take important variables into consideration as an appropriate metric for quality. Electronic records were searched for patients with a diagnosis of HF who died from any cause during hospitalization or within 30-days of admission at a single institution. Researchers found:

  • There were 646 HF-related admissions among 530 patients (1.2 admissions/patient).
  • 67 of 530 (13%) patients died: 35 (52%) during hospitalization and 32 (48%) after discharge but within 30 days of admission.
  • 51 (76%) patients died from HF and 16 (24%) from other causes.
  • 55 (82%) patients were classified as AHA Stage-D, 58 (87%) as NYHA Class-IV, and 30 (45%) had right-ventricular systolic dysfunction.
  • 57(85%) patients had a DNR status.
  • No care gaps were identified that contributed to mortality.

Faillace RT, Yost GW, Chugh Y, et al. Is 30-day mortality after admission for heart failure an appropriate metric for quality? [Published online ahead of print September 20, 2017]. Am J Med. doi:10.1016/j.amjmed.2017.09.007.

This Week's Must Reads

No Need to Alter TKI Treatment in These Patients, Am J Hematol; ePub 2017 Oct 13; Alhuraiji, et al

Insurance Subsidy Impact on New TKI Users Assessed, Cancer; ePub 2017 Oct 4; Shen, Zhao, Liu, et al

Ruxolitinib in Patients Who Can’t Take Hydroxyurea, Blood; 2017 Oct 12; Verstovsek, Passamonti, et al

Socioeconomic Status Impact on Chronic GVHD, Biol Blood Marrow Transplant; ePub 2017 Oct 12; Hamilton, et al

Impact of Precision-Dosing Strategy with IVIG, Pharmacotherapy; ePub 2017 Oct 13; Stump, et al

Must Reads in Cardiology

Assessing CCTA for Patients with Suspected CAD, JAMA Intern Med; ePub 2017 Oct 2; Foy, et al

Rivaroxaban + Aspirin for CV Prevention, N Engl J Med; 2017 Oct 5; Eikelboom, et al

Impact of Heart Failure on Body Composition, Circ Heart Fail; ePub 2017 Sep 12; Forman, et al

30-Day Mortality Rate After Admission for HF, Am J Med; ePub 2017 Sep 20; Faillace, et al

Assessing the Accuracy of Self-Reported HF, J Card Fail; ePub 2017 Sep 8; Camplain, et al